• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Oligodendroglioma - Pipeline Review, H1 2012 Product Image

Oligodendroglioma - Pipeline Review, H1 2012

  • ID: 2114498
  • April 2012
  • 70 pages
  • Global Markets Direct

Oligodendroglioma – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Oligodendroglioma - Pipeline Review, H1 2012', provides an overview of the Oligodendroglioma therapeutic pipeline. This report provides information on the therapeutic development for Oligodendroglioma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Oligodendroglioma. 'Oligodendroglioma - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Oligodendroglioma.
- A review of the Oligodendroglioma products under development by companies and universities/research institutes READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Oligodendroglioma Overview
Therapeutics Development
An Overview of Pipeline Products for Oligodendroglioma
Oligodendroglioma Therapeutics under Development by Companies
Oligodendroglioma Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Oligodendroglioma Therapeutics – Products under Development by Companies
Oligodendroglioma Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Oligodendroglioma Therapeutics Development
Tocagen Inc
Oligodendroglioma – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
CPT-11 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MLN-518 + Bevacizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carboplatin + Cisplatin + Cyclophosphamide + Etoposide + Methotrexate + Temozolomide + Thiotepa + Vincristine + Stem cell transplantation + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gleevec - Drug Profile
Product Description
Mechanism of Action
R&D Progress
procarbazine hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Temozolomide + Busulfan + Thiotepa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lomustine + Procarbazine + Vincristine + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TEMODAR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Temozolomide + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Topotecan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Temozolomide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bevacizumab + Irinotecan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Peptide Vaccine + Poly-ICLC - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bendamustine Hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Temozolomide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RAD001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Aminolevulinic acid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carboplatin + Temozolomide + Thiotepa + Vincristine + Stem Cell Transplantion + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Imatinib Mesylate + Temozolomide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Etoposide + Melphalan + Carboplatin + Sodium Thiosulfate + Filgrastim + Neulasta - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Poly-ICLC - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Alloreactive Cytotoxic T Lymphocytes + Interleukin-2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Autologous Tumor Cell Vaccine + Sargramostim + Muromonab-CD3 + Aldesleukin + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Toca 511 + Toca FC - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AMD3100 + Avastin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BIBF 1120 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lomustine + Procarbazine + Vincristine + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Oligodendroglioma Therapeutics – Drug Profile Updates
Oligodendroglioma Therapeutics – Discontinued Products
Oligodendroglioma Therapeutics - Dormant Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Oligodendroglioma, H1 2012
Products under Development for Oligodendroglioma – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Tocagen Inc, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Oligodendroglioma Therapeutics – Drug Profile Updates
Oligodendroglioma Therapeutics – Discontinued Products
Oligodendroglioma Therapeutics – Dormant Products

List of Figures
Number of Products under Development for Oligodendroglioma, H1 2012
Products under Development for Oligodendroglioma – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos